Asia Executives On The Move: Comings And Goings At BeiGene, Harbour BioMed, TLC, GC Pharma
New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure of BeiGene's chief commercial officer and a new chief strategy officer and CMO at Harbour Biomed.
You may also be interested in...
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.